Written Question: Vaccines
(Source: European Parliament)
Date submitted: 9 February 2021
Question for written answer E-000781/2021
to the Commission
Nicolás González Casares (S&D)
In recent days we have become aware of numerous subcontracting agreements that various COVID-19 vaccine-producing companies – which hold supply contracts with the EU – have signed with other companies in the sector so as to boost vaccine production. This is good news.
Although we know little about these contracts due to the limitations and obstacles imposed on Parliament in its scrutiny over them, we understand that some of the agreements that companies contracted to the Commission have signed with third parties could impinge on their contracts with the EU. They could also entail relocating the production of vaccines, whose development was supported by the EU, to third countries.
1. Does the Commission have any mechanism in place to verify that these parallel contracts are in accordance with the terms of the contract signed with the EU?
2. Has information been requested from the contractors to verify that the contracts do not harm European interests in terms of supply and distribution, in view of what happened with AstraZeneca?
3. Does the Commission not think that the European money invested in the development of these vaccines should guarantee they are produced in the EU and prevent any offshoring under these new agreements?